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A nalysis  of C um ulative  P ro b a b il i t ie s  Show s T h at  the  
Efficacy o f  5 H T 3 A n tagon is t  P ro p h y la x is  Is  
Not M ain ta in ed
»
By Ronald de Wit, Paul I.M. Schmitz, Jaap Verweij, Maureen de Boer-Dennert, Pieter H.M. de Mulder,
André S.T. Planting, Maria E.L. van der Burg, and Gerrit Stoter
Purpose: Several investigators have reported that the 
efficacy o f 5HT3 receptor antagonists is maintained over 
repeated cycles of chemotherapy. These investigators 
presented conditional probabilities of protection. Be­
cause conditional analyses by definition only include pa­
tients w ith  protection in previous cycles, the results are 
flattered.
Patients and Methods: We applied a novel statistical 
approach to investigate whether the efficacy of the 5HT3 
receptor antagonist ICS 205-930 (tropisetron) is main­
tained over repeated cycles of w eekly high-dose cis- 
platin. Overall protection was determined based on cu­
mulative probabilities w ith the Kaplan-Meier method. 
Complete protection was calculated w ith  a three state 
model fo r transitional probabilities. Eighty-three patients 
were studied.
N AUSEA and vomiting are the most distressing as­
pects of cancer chemotherapy.1 The prevention and 
treatment of these symptoms was greatly improved with 
the development of selective 5HT3 receptor antagonists, 
which yield control of nausea and vomiting in more than 
70% of cisplatin-treated patients in the first cycle of che­
motherapy.2'4
The issue of maintained effectiveness of these antiemet­
ics over repeated cycles has been scarcely addressed, and 
in the few studies published different statistical analyses 
were used, which hampers the interpretation.5'8 Several 
investigators have reported that the efficacy of 5HT3 antag­
onists is maintained over repeated cycles of chemotherapy. 
The statistical method used in these publications was based 
on the calculation of conditional probabilities. The condi­
tion is that protection failure did not occur in the previous 
cycles. Therefore, these analyses by definition include only 
patients with protection in previous cycles. This leads to 
an overestimation of the sustainment of protection.
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Results: Over s ix consecutive cycles, protection  
against both acute and delayed emesis decreased sig­
nificantly. The in itia l complete and overall protection  
rates against acute emesis of 71 % and 95%, respectively, 
decreased to 43% and 72% in the sixth cycle o f chemo­
therapy. S im ilarly, the protection rates o f 31% and 68%  
against delayed emesis decreased to 6% and 40%, re­
spectively.
Conclusion: We conclude that overall and complete 
long-term protection is more accurately measured by cu­
mulative probabilities than w ith  a method that is based 
on conditional probabilities. Our statistical approach  
shows that the efficacy o f 5HT3 antagonists is not m a in ' 
tained.
J  Clin Oncol 14:644-651. © 1996 by American So­
ciety of Clinical Oncology,
To avoid this, we applied the Kaplan-Meier method 
and introduced a three-state model for transitional proba­
bilities. These statistical tools were used to investigate the 
efficacy of the 5HT3 antagonist ICS 205-930 (tropisetron) 
over multiple cycles of weekly high-dose cisplatin. Be­
cause it is well known that 5HT3 antagonists do not prop­
erly control delayed emesis, we analyzed the effect on 
acute and delayed nausea and vomiting separately.
PATIENTS AND METHODS
Patients were treated in the framework of two prospective phase
II studies. One was designed for patients with head and neck cancer 
who received single-agent cisplatin 80 mg/m2 weekly for 6 weeks. 
The other was for patients with non-small-cell lung cancer, mela­
noma, cancer of unknown primary, and mesothelioma who received 
cisplatin 70 mg/m2 weekly on weeks 1, 2, 3, 5, 6, and 7, with 
etoposide 50 mg orally days 1 through 15 and 29 through 43.,J U
Eligibility criteria required the following: no previous chemother­
apy; World Health Organization (WHO) performance status ^  2; 
leukocyte count greater than 3,000/^L; platelet count greater than 
75,000/^L; serum creatinine level less than 120 ¿zmol/L or creatinine 
clearance greater than 60 mL/min; and bilirubin level less than 25 
//mol/L. Exclusion criteria were the use of drugs that can influence 
nausea, vomiting, or diarrhea, such as corticosteroids, other anti­
emetics, narcotics (unless chronically administered), or benzodiaze­
pines (except small doses given as sleeping medication). Also ex­
cluded were patients with preexistent nausea and/or vomiting, brain 
metastases or leptomeningeal involvement, and alcohol abuse (more 
than 3 U/d).
The chemotherapy protocols did not allow for chemotherapy dose 
reductions. If at scheduled retreatment leukocyte count was less than 
2,500//u.L and/or platelet count was less than 75,000//zL, treatment 
was postponed until recovery. In case of treatment delay of more 
than 2 weeks or the occurrence of neurotoxicity or renal toxicity
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greater than grade 1, the patient was taken off study. Informed 
consent was obtained from all patients.
Cisplatin was administered in 3% hypertonic saline over 3 hours, 
preceded by 1,000 mL of dextrose saline over 4 hours, and followed 
by 2,000 mL dextrose saline over 8 hours. Tropisetron 5 mg intrave­
nously (IV) was administered over 15 minutes just before the infu­
sion of cisplatin, followed by a daily oral dose of 5 mg before 
breakfast on days 2 through 5.12
Efficacy parameters for tropisetron were nausea and vomiting. 
The duration of nausea and the number of retches and vomits were 
recorded daily by nursing charts during the first 24 hours and by 
patient diary cards during days 1 through 5. The following definitions 
were used: complete protection, no nausea and vomiting; partial 
protection, one to four vomits or dry retches and/or 4 hours 
nausea; overall protection, the sum of complete and partial protec­
tion; protection failure, more than four vomits and/or more than 4 
hours nausea; withdrawal, drop-out for reasons other than antiemetic 
treatment failure, eg, discontinuation of chemotherapy because tu­
mor progression, decline in performance status, toxicity other than 
nausea and vomiting, the first prescription or an increase in the 
dosages o f  narcotic analgesics or bezodiazepines, and incomplete 
follow-up.
Patients with protection failure on day 1 were not eligible for 
further tropisetron treatment and were taken off study. Patients who 
experienced failure during days 2 through 5, but with complete or 
partial protection on day 1, continued tropisetron in subsequent cy­
cles during day 1, until protection failure occurred. The decision to 
withdraw or censor was made either at the completion o f  the first 
24 hours (acute emesis) or at the protocol date of the next cycle 
(delayed emesis). Patients who were withdrawn after completion o f  
the first 24 hours were available for the acute emesis protection 
evaluation.
Written informed consent was obtained from all patients, and the 
study was conductcd according to the guidelines o f  the institutional 
review boards.
Statistical Analysis
The primary aim was to accurately determine overall protection 
against acute emesis over a total of six chemotherapy cycles. It was 
required that the SE of overall protection in cycle six should be <  
7%. Assuming a constant overall protection rate of 80% in each 
cycle, a total of 100 patients in the first cycle would result in approxi­
mately 33 patients at the start of cycle six. With 33 patients, the SE 
of a rate of 80% is 1%. Consequently, approximately 100 patients 
were planned to enter onto the study. Acute and delayed emesis 
were analyzed separately with overall and complete protection as 
end points. For delayed emesis (days 2 through 5), a worst day 
analysis was used because this is the most realistic approach to 
measure protection for the entire 4-day period over multiple cycles
o f  chemotherapy.
Cumulative protection of overall protection over multiple cycles
was calculated with the Kaplan-Meier method,13 where protection 
failure was the end point. The calculations were derived from product 
and addition rules for probabilities and Bayes theorem .14 Confidence 
intervals of overall protection were calculated with Greenwood’s
formula.15
A realistic analysis o f  complete protection is complicated because 
of the possible transitions between three states (complete protection, 
partial protection, and protection failure); a situation for which the 
Kaplan-Meier analysis is unsuitable. Therefore, we applied a three- 
state Markov model for transitional probabilities, where transitional
probabilities are independent of the results in prior states, and in 
which the transitional probabilities vary over time .16 Transitional 
probabilities were estimated from simple tabulations. The probability 
of complete protection in a given cycle follows from the sum of the 
products of transitional and state probabilities in previous cycles. 
SEs and confidence intervals o f  complete protection in this model 
were calculated with a bootstrap technique (see Appendix).
RESULTS
Between January 1992 and July 1993, 83 eligible pa­
tients were entered onto the study. Patient characteristics 
are listed in Table 1. The majority of patients were male, 
which can be attributed to the male preponderance of the 
selected tumors.
All patients were assessable for at least the first 24 
hours of the first cycle of chemotherapy. A total of 278 
cycles of IV tropisetron on day 1 and 209 cycles of oral 
tropisetron on days 2 through 5 were administered. Table 
2 lists the number of assessable patients per cycle and 
the number of patients who were taken off study in subse­
quent cycles for non-cause-specific reasons. The reasons 
for withdrawal are listed in Table 3. To date, eight patients 
were dropped from the study because of delayed emesis 
protection failure despite protection on day 1. Because 
these patients, in point of fact, had protection against 
acute emesis, they are included in the analysis as such, 
and considered as withdrawals in subsequent cycles.
In the delayed protection analysis, 75 patients were 
included. Two patients did not receive tropisetron on days 
2 through 5 because they had protection failure on day 1 
of the first cycle, and six others were not assessable in 
the first cycle because of incomplete follow-up (three 
patients), prescription of benzodiazepines (one patient), 
and no intake of tropisetron (two patients). Five patients
Table 1. Patient Characteristics
No. of Pafienfs (N = 83)
Median age, years 55
Range 30-72
Male/female 6 3 /2 0
W HO  performance status
Median 1
Range 0-2
Primary tumor site
Head and neck cancer 36
Non-small-cell lung cancer 16
Melanoma 9
Cancer unknown primary 8
Mesothelioma 12
Cervical carcinoma 2
Chemotherapy
Cisplatin 80 m g/m 2 36
Cisplatin 70 m g/m 2 +  etoposide 50  mg 47
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Table 2. Assessable and Withdrawn Patients Per Cycle
Cycle
1 2 3 4 5 6
Day 1
No. of patients 83 01 49 3ó 27 22
Withdrawals 18 8 10 ó 5 —
Days 2-5
No. of patients 75 41 33 27 21 14
Withdrawals 10 2 4 3 7 —
developed protection failure against acute emesis during 
subsequent cycles and were included as withdrawals in 
the delayed protection analysis.
Figure 1 shows the overall protection rates and 95% 
confidence limits for acute and delayed emesis. Figure 2 
shows this information for complete protection. It can be 
seen from these figures that the complete and overall 
protection rates for delayed emesis are lower than for 
acute emesis, and that these rates decrease significantly 
over the treatment period of six cycles. To date, initial 
complete and overall protection rates against acute emesis 
of 71% and 95%, respectively, decreased to 43% and 
72%, and the protection rates against delayed emesis of 
31% and 68%, respectively, decreased to 6% and 40%, 
The SE of overall protection in cycle six was 0.046. As 
an example of the calculation of protection during the six 
cycles, Table A1 in the Appendix gives the distribution 
of protection for acute emesis; the text in the Appendix 
also provides the calculation of protection rates for acute 
emesis for both cumulative and conditional rates.
Protection failures regarding delayed emesis were 
mainly observed on days 2 and 3. Using a worst-day 
analysis, the complete protection rate during days 2 
through 5 of the first cycle was as low as 31% (Fig 
2). However, when a day-by-day analysis was used, the 
protection rates in the first cycle were 40%, 61%, 78%,
Table 3. Reasons for Withdrawal
Day 1 Days 2-5
Stopped chemotherapy
Tumor progression/other therapy 14 8
Refusal 8 2
Toxicity other than emesis 4 2
Stopped tropisetron
Prescription of narcotics, sedatives, or corticosteroids 6 1
Failure days 2-5 8 NA
Failure day 1 NA 5
Refusal 2 1
Miscellaneous 5 7
Abbreviation: NA, not applicable.
1 -
/-s ^
CL *9 “
a.
+  a -
a  n
u
w  .7 -
c
O C _•ri «O
4-1
U .5 -
o
C_ .4 ~
CL
'3 “r—<
ro
L. .2 “
cu
> , -Ja  .1 “
o -
C)
Acute emesis
o
o
o
o
o
o
()
C) o
Delayed emesis
o
1 2 3 4 5 6
course
Fig 1. Overall protection against acute (upper circles) and delayed 
(lower circles) emesis. Bars represent 95% confidence limits.
and 84% for days 2, 3, 4, and 5, respectively. A similar 
pattern was observed in the subsequent cycles (data not 
shown).
Median age, sex, and chemotherapy protocol were ana­
lyzed in relationship to overall protection. Only age was 
found to have a borderline significant influence on the 
overall protection on day 1; we observed that younger 
patients were less well protected (P = .04). Sex (P = .84) 
and chemotherapy protocol (P = .34) were not significant 
variables.
DISCUSSION
Virtually all clinical investigations with 5HT3 an­
tagonists have focused on chemotherapy-naive pa-
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Fig 2. Complete protection against acute {upper circles) and de 
layed (lower circles) emesis. Bars represent 95% confidence limits.
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tients who were either studied in the first chemother- 
apy cycle only, or included in a cross-over design for 
the first two cycles of chemotherapy. The issue of 
effectiveness of these antiemetics over multiple cycles 
has been inadequately addressed.
Decreasing efficacy has been demonstrated with the 
use of conventional antiemetic agents during consecu­
tive cycles of both cisplatin- and non-cisplatin-con- 
taining chemotherapy.17,18 Few data exist on the sus­
tainment of efficacy of 5HT3 antagonists. One study 
of ondansetron over six cycles of non-cisplatin-con- 
taining chemotherapy suggested decreasing protec­
tion/’ Recently, the Italian Group for Antiemetic Re- 
search19 reported that the efficacy of the combination 
of ondansetron and dexamethason was maintained 
during three cycles of cisplatin chemotherapy, 
whereas the efficacy of a metoclopramide combination 
was not maintained. In their analysis, only patients 
who were able to complete all three cycles of chemo­
therapy were included. Of note, these investigators 
clearly demonstrated that the protection obtained in 
previous chemotherapy cycles is the most important 
prognostic factor for sustainment of efficacy.
In 1992 and 1993, three independent investigators 
reported that the antiemetic efficacy of 5HT3 receptor 
antagonists was maintained after multiple cycles of 
chemotherapy.i,7,s In these studies, approximately one 
third of the patients were treated with cisplatin chemo­
therapy regimens at conventional 3- to 4-week inter­
vals. These investigators used the method of condi­
tional probabilities of protection for their analyses. 
By definition, this type of analysis includes only pa­
tients who are protected in previous cycles, which 
leads to selection of favorable patients and therefore 
to an overestimation of the sustainment of protection. 
This bias can be avoided with the calculation of cumu­
lative probabilities, including all protection failures 
in the sum of failures during subsequent cycles, and
incorporating censoring of the data due to non-cause- 
specific withdrawals in previous cycles.
We have investigated the efficacy of the 5HT3 antago­
nist tropisetron over multiple cycles of chemotherapy 
with the Kaplan-Meier method for the measurement of 
overall protection and with a three-state model for tran­
sitional probabilities for the calculation of ccinp,!;;j  
protection.
Using these methods, we found that protection 
against both acute and delayed emesis decreased sig­
nificantly. Initial complete and overall protection rates 
against acute emesis were 71% and 95%, respectively, 
and decreased to 43% and 72%. The protection rates 
against delayed emesis of 31% and 68%, respectively, 
decreased to 6% and 40%.
To illustrate the difference in outcome of the two 
methods of analysis, Fig 3 shows both the conditional 
and cumulative protection rates for acute emesis. It can 
be seen that the conditional analysis flatters the results.
Our findings that tropisetron was substantially less 
protective against delayed nausea and vomiting are in 
accord with previous reports, indicating that 5HT3 an­
tagonists do not properly control delayed emesis.20'22 
However, the low complete protection rate of 31% in 
the first cycle is partly because of our use of a worst- 
day analysis instead of a day-by-day analysis. Because 
the primary aim of our study was to investigate whether 
the efficacy of a 5HT3 antagonist is maintained over 
multiple cycles of chemotherapy, we applied the worst- 
day analysis.
We conclude that the Kaplan-Meier method for the 
measurement of overall protection and the three-state 
model for transitional probabilities for the measurement 
of complete protection are the proper methods to ana- 
lyzeaccurately the efficacy of antiemetics over multiple 
cycles of chemotherapy. This approach shows that the 
efficacy of initially highly effective 5HT3 receptor an­
tagonist prophylaxis is not maintained.
Fig 3. Difference in protec­
tion a g a i n s t  acute emesis related 
to the conditional versus cumula­
tive calculation method.
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APPENDIX
The overall accounting of patients is given in the equation:
Ni+1 = Ni - F , - W ,
where Nj+i is the number entering cycle i +  1; N, is the number entering cycle i; Fj is the number of protection failures in cycle i; and Wjis 
the number of withdrawals after cycle i prior to cycle i +  1. (For example, = N t — F t — W 1 : 61 =  83 — 4 — 18.)
Table A l, Distribution of Protection for Acute Emesis During Six Cycles
Cycle 1:
Cycle 2
cycle I
Cycle 3:
cycle 2
CP
PP
CP
PP
cycle 1 
CP PP PF
42 15 4
cycle 3 
CP PP PF
34 12 3
59 20 4
cycle 2
CP PP PF
36 8 2
6 7 2
total
83
total
46
15
61
29 7 2
5 5 1
total
38
11
49
Cycle 4:
cycle 3
Cycle 5:
cycle 4
Cyclc 6:
cycle 5
cycle 4 
CP PP PF total
CP 20 5 2 27
PP 2 6 1 9
22 11 3 36
cycle 5
CP PP PF total
CP 16 2 0 18
PP 0 9 0 9
16 11 0 27
cycle 6
CP PP PF total
CP 10 4 0 14
PP 3 4 1 8
13 8 1 22
Abbreviations: CP, complete protection; PP, partial protection; PF, protection failure.
CALCULATION OF CUMULATIVE PROTECTION RATES WITH THE KAPLAN-MEIER METHOD
For the calculation of cumulative protection rates with the Kaplan-Meier method, two variables are defined for each patient: when no 
protection failure occurs in cycles one to six, and when protection failure occurs in one of the cycles one to six. Time 1, two to six is the 
cycle number when protection failure occurs or last cycle number of follow-up.
Calculation of the conditional protection rates and the cumulative protection rates with the Kaplan-Meier method for acute emesis is as 
follows:
Cycle 1: P(OP) = (59 + 20)/83 -  0.95
Cycle 2:
Cycle 3:
Conditional:
P(OP cycle 2 | OP in cycle 1) =
= (42 + 15)/61 = 0.93 
Cumulative:
P(OP in cycle 2) =
= P(OP in cycle 2 | OP in cycle 1) X P (OP in cycle 1 ) 
=  (0.93) (0.95) =  0.88
Conditional:
P(OP in cycle 3 | OP in cycle 2) =
=  (34 + 12)/49 = 0.94
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Cumulative:
P(OP in cycle 3) =
=  P(OP in cycle 3 | OP in cycle 2) X P(OP in cycle 2) 
=  (0.94) (0.88) =  0.83
Analogously:
Cycle 4: conditional: (22 + Il)/36
cumulative: (0.92) (0.83) =
=* 0.92 
* 0.76
Cycle 5: conditional: (16 +  ll) /27  = 1.0
cumulative (1.0) (0.76) = 0.76
Cyclc 6: conditional: (13 +  8)/22 -  0.95
cumulative: (0.95) (0.76) =  0.72
CALCULATION OF COMPLETE PROTECTION RATES USING A TRANSITIONAL-PROBABIUTY MODEL
For each cycle, three different states can be distinguished: complete protection (CP), partial protection (PP), and protection failure (PF). 
PF is a so-called ‘‘absorbing state” : once reached it cannot be left because the paLient goes off study. A  CP or PP can change either to a 
CP, or to a PP or a PF in the next cycle. Between two states in two consecutive cycles, the transition-probability can easily be estimated 
from a crosstable.
cycle I cycle 2 course 6
The transitional probabilities are as follows (i =  1, 2 , 3, 4, 5):
P(CP,H CP,)
P(CPi+1 PPi)
P(CP1+, PF,) = 0
p(ppi+. CPi)
p(ppj+ 1 PPi)
PCPPi-1-1 *0 n o
P(PF,+t CP,) = 1
P(PFi+, PPi) = 1
P(PFi+i PFi) = 1
-  P(CPji-, | CPi) -  P(PPi(., | CP,)
-  P(CPii-H
The stale probabilities in cycle one are (# denotes number):
P(CP, ) =
PPi) -  P(PPm I PPi)
#CP in cycle 1
P(PP,) =
# treated patients in cycle 1 
#PP in cycle 1
#  treated patients in cycle 1
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P(PF|) = 1 -  P(CP,) -  P(PP,)
From these probabilities and the Uansition probabilities the protection rates are calculated as follows:
P(CP,+I) =  P(CPi) P(CPi+, | CP,) + P(PPi) P(CP i+1 | PP,) 
P(PPi+1) =  P(CPi) P(PPi+, | CPi) + P(PPj) P(PPm | PPi) 
P(PFi+I) -  1 -  P(CP,+I) -  P(PPi,i)
Application of these formulas to the data for acute emesis gives the following results:
Cycle 1: P(CP) = 59/83 -  0.71
P(PP) = 20/83 =  0.24
Cycle 2: Conditional protection probabilities:
P(CP in cycle 2 | CP in cycle 1 ) =
=  36/46 = 0.78
P(CP in cycle 2 | PP in cycle 1) =
=  6/15 -  0.40
P(PP in cycle 2 | PP in cycle 1) =
=  8/46 =  0.17
P(PP in cycle 2 | PP in cycle 1) =
=  7/15 *  0.47
Cumulative probabilities:
P(CP in cycle 2 ) =
=  P(CP in cycle 2 | CP in cycle 1) X P(CP in cycle 1) +
P(CP in cycle 2 | PP in cycle 1) X P(PP in cycle 1) =
=  (0.78) (0.71) + (0.40) (0.24) =  0.65 
P(PP in cycle 2) =
= P (PP in cycle 2 | CP in cycle 1) X P(CP in cycle 1) +
P(PP in cycle 2 | PP in cycle I) X P(PP in cycle 1) —
-  (0.17) (0.71) + (0.47) (0.24) =  0.23
Calculations for cycles three through six are analogous and summarized in the following table:
cycle i 1 2
i
3 4 5 6
P (CPi) 0.71 0.65 0.60 0.49 0.44 0.43
P (PPi) 0.24 0.23 0.22 0.27 0.32 0.29
P (CPi+i | CPj) 0.78 0.76 0.74 0.89 0.71 ----------
P (C Pm  |PPj) 0.40 0.46 0.22 0 0.37 ----------
P iP P i. i lC P i) 0.17 0.18 0.19 0.11 0.29 ----------
P (P P i+,|PPi) 0.47 0.46 0.67 1.00 0.50 ----------
The SEs and confidence intervals of complete protection, P(CPj), i = K2 , ___ _ 6 are calculated with the bootstrap method, in particular
using the data resampling approach.22,23 Two thousand bootstrap samples were generated; each bootstrap sample was generated with 
replacement from the empirical distribution of the data and was of the same size as the original dataset. A 95% bootstrap-percentile 
confidencc interval finally follows from:
P(CPi) -  (PoW CPi) -  P(CP,)} <  P(CP|) <  P(CPi) -  {p L sCCP.) -  P(CP,)J
A
where P(CPi) is he bootstrap estimator for P(CP,) and pJomCCP,) and Po.wtCP.) are the 2.5th and 97.5th percentile of the 2,000 bootsttap 
sample distributi >n of P*(CP,).
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